JP2008511652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008511652A5 JP2008511652A5 JP2007530256A JP2007530256A JP2008511652A5 JP 2008511652 A5 JP2008511652 A5 JP 2008511652A5 JP 2007530256 A JP2007530256 A JP 2007530256A JP 2007530256 A JP2007530256 A JP 2007530256A JP 2008511652 A5 JP2008511652 A5 JP 2008511652A5
- Authority
- JP
- Japan
- Prior art keywords
- growth factor
- pharmaceutical composition
- product
- wound healing
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 239000000047 product Substances 0.000 claims 24
- 230000029663 wound healing Effects 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 239000003607 modifier Substances 0.000 claims 11
- 230000008512 biological response Effects 0.000 claims 10
- 102000000588 Interleukin-2 Human genes 0.000 claims 8
- 108010002350 Interleukin-2 Proteins 0.000 claims 8
- 102000004388 Interleukin-4 Human genes 0.000 claims 8
- 108090000978 Interleukin-4 Proteins 0.000 claims 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 8
- 230000004614 tumor growth Effects 0.000 claims 8
- 102000003390 tumor necrosis factor Human genes 0.000 claims 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 7
- 108010076119 Caseins Proteins 0.000 claims 7
- 102000015696 Interleukins Human genes 0.000 claims 7
- 108010063738 Interleukins Proteins 0.000 claims 7
- 239000001888 Peptone Substances 0.000 claims 7
- 108010080698 Peptones Proteins 0.000 claims 7
- 102000007562 Serum Albumin Human genes 0.000 claims 7
- 108010071390 Serum Albumin Proteins 0.000 claims 7
- 206010052428 Wound Diseases 0.000 claims 7
- 208000027418 Wounds and injury Diseases 0.000 claims 7
- 238000010521 absorption reaction Methods 0.000 claims 7
- 239000005018 casein Substances 0.000 claims 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 7
- 235000021240 caseins Nutrition 0.000 claims 7
- 239000007857 degradation product Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 235000019319 peptone Nutrition 0.000 claims 7
- 230000001737 promoting effect Effects 0.000 claims 7
- 108010074328 Interferon-gamma Proteins 0.000 claims 6
- 102000008070 Interferon-gamma Human genes 0.000 claims 6
- 238000000862 absorption spectrum Methods 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 6
- 229960003130 interferon gamma Drugs 0.000 claims 6
- 230000031700 light absorption Effects 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 4
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 4
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims 4
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims 4
- 102400001368 Epidermal growth factor Human genes 0.000 claims 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 4
- 102000003812 Interleukin-15 Human genes 0.000 claims 4
- 108090000172 Interleukin-15 Proteins 0.000 claims 4
- 108010002616 Interleukin-5 Proteins 0.000 claims 4
- 102000000743 Interleukin-5 Human genes 0.000 claims 4
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 4
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 4
- 102000013275 Somatomedins Human genes 0.000 claims 4
- 229960005305 adenosine Drugs 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229940116977 epidermal growth factor Drugs 0.000 claims 4
- 229940028885 interleukin-4 Drugs 0.000 claims 4
- 229940100601 interleukin-6 Drugs 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 3
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 claims 3
- 108090000467 Interferon-beta Proteins 0.000 claims 3
- 102000003996 Interferon-beta Human genes 0.000 claims 3
- 102100036154 Platelet basic protein Human genes 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- 229960001388 interferon-beta Drugs 0.000 claims 3
- 102000049853 macrophage stimulating protein Human genes 0.000 claims 3
- 108010053292 macrophage stimulating protein Proteins 0.000 claims 3
- 206010011985 Decubitus ulcer Diseases 0.000 claims 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims 2
- 208000002847 Surgical Wound Diseases 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60532004P | 2004-08-27 | 2004-08-27 | |
| PCT/US2005/030798 WO2006026604A2 (en) | 2004-08-27 | 2005-08-29 | Methods for promoting wound healing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008511652A JP2008511652A (ja) | 2008-04-17 |
| JP2008511652A5 true JP2008511652A5 (enExample) | 2008-10-16 |
Family
ID=36000687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530256A Pending JP2008511652A (ja) | 2004-08-27 | 2005-08-29 | 創傷治癒の促進方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1804817A4 (enExample) |
| JP (1) | JP2008511652A (enExample) |
| AU (1) | AU2005279921A1 (enExample) |
| CA (1) | CA2578212A1 (enExample) |
| WO (1) | WO2006026604A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6528098B2 (en) | 1996-10-22 | 2003-03-04 | Advanced Viral Research Corp. | Preparation of a therapeutic composition |
| JP5661777B2 (ja) * | 2009-09-29 | 2015-01-28 | ユナイテッド・テクノロジーズ・ユーティー・アクチェンゲゼルシャフト | 組換え型ヒトインターロイキン−１を含む口腔ケア組成物 |
| ES2715105T3 (es) | 2013-04-18 | 2019-05-31 | Qbiotics Ltd | Métodos y composiciones para la cicatrización de heridas |
| CN108339112B (zh) * | 2016-12-30 | 2023-04-21 | 亚宝药业集团股份有限公司 | 一种用于促进创伤愈合、褥疮修复、术后应激性溃疡愈合的营养组合物 |
| WO2025049974A1 (en) * | 2023-09-01 | 2025-03-06 | Eom Pharmaceuticals Inc. | Methods of treating inflammatory bowel diseases |
| CN118121594B (zh) * | 2024-05-06 | 2024-07-02 | 广州市朝利良生物科技有限公司 | Eh-p006n在制备促进伤口愈合药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849196A (en) * | 1996-10-07 | 1998-12-15 | Immune Modulation Maximum | Composition containing peptides and nucleic acids and methods of making same |
| US6528098B2 (en) * | 1996-10-22 | 2003-03-04 | Advanced Viral Research Corp. | Preparation of a therapeutic composition |
| US6303153B1 (en) * | 1996-10-22 | 2001-10-16 | Advanced Viral Research Corp. | Preparation of a therapeutic composition |
| AU6968098A (en) * | 1997-04-15 | 1998-11-11 | Advanced Viral Research Corp. | Topical treatment of skin diseases and eye afflictions |
| US5807839A (en) * | 1997-04-15 | 1998-09-15 | Advanced Viral Research Corp. | Method for stimulating red blood cell production |
| EP0975216A4 (en) * | 1997-04-15 | 2002-05-02 | Advanced Viral Res Corp | METHOD OF TREATING PAPILLOMA VIRUS INFECTIONS |
| US5902786A (en) * | 1997-04-15 | 1999-05-11 | Advanced Viral Research Corp. | Treatment of basal cell carcinoma with product R, a peptide-nucleic acid preparation |
| US7439234B2 (en) * | 1997-04-15 | 2008-10-21 | Advanced Viral Research Corporation | Method for treating cancer patients undergoing chemotherapy |
| US20020107184A1 (en) * | 1997-11-04 | 2002-08-08 | Shalom Z. Hirschman | Method for treating melanoma |
-
2005
- 2005-08-29 JP JP2007530256A patent/JP2008511652A/ja active Pending
- 2005-08-29 AU AU2005279921A patent/AU2005279921A1/en not_active Abandoned
- 2005-08-29 CA CA002578212A patent/CA2578212A1/en not_active Abandoned
- 2005-08-29 EP EP05795551A patent/EP1804817A4/en not_active Withdrawn
- 2005-08-29 WO PCT/US2005/030798 patent/WO2006026604A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Falanga et al. | Wound healing | |
| ES2358645T3 (es) | Composiciones de lactoferrina y métodos de tratamiento de la úlcera diabética. | |
| RU2128056C1 (ru) | Способы и препараты для лечения заболеваний интерфероном, характеризующиеся сниженными побочными эффектами | |
| CA2133831A1 (en) | Low toxicity interleukin-2 analogues for use in immunotherapy | |
| Thornton et al. | Wound healing in sepsis and trauma | |
| AU2014216730B2 (en) | Short bio-active peptides for promoting wound healing | |
| JP2008511652A5 (enExample) | ||
| AU2004277954A1 (en) | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions | |
| JP2007512377A5 (enExample) | ||
| EP0563060B1 (en) | Use of IL-4 and TNF for the preparation of a medicament for the treatment of tumour cells | |
| Azoulay et al. | Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients? | |
| KR100234870B1 (ko) | 제조합 콜로니 자극인자-1을 함유하는 약제학적 조성물 | |
| Veldhuis et al. | Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial. | |
| Elbaz et al. | Tumor necrosis factor and human acute leukemia | |
| Larrick et al. | Native cytokine antagonists | |
| West | Role of cytokines in leukocyte activation: phagocytic cells | |
| CN1990045A (zh) | 一种新型高效烧烫伤类贴剂及其制备方法 | |
| JP2008511652A (ja) | 創傷治癒の促進方法 | |
| JP2005500390A5 (enExample) | ||
| ElAttar et al. | Prostaglandin E2 antagonizes gingival fibroblast proliferation stimulated by interleukin-1β | |
| JP4578067B2 (ja) | 局所医薬組成物 | |
| CN115894660B (zh) | 聚乙二醇衍生物修饰的白介素12及其制备方法和应用 | |
| EP2089050A2 (en) | Il- 17b for use in wound healing | |
| WO2000057902A1 (en) | Method and pharmaceutical composition for wound healing | |
| Hiraoka et al. | Differential activation of polymorphonuclear leukocytes from peripheral blood and exudate in surgical patients |